Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Project Focuses on Discovery of Early Cancer in Women

By Labmedica International staff writers
Posted on 26 Feb 2013
Print article
Scientists are focusing on the early detection of breast and ovarian cancer with the goal of developing a test to identify tumor markers present in blood and link these markers to the presence of cancer.

Partners in the project called EpiFemCare, include GATC Biotech (Constance Germany), which will manage sample processing, i.e., the DNA isolation from serum and the reduced representation bisulfite sequencing from serum derived DNA. This method analyses DNA methylation in normal and tumor DNA.

In addition, 6 institutions from 5 European countries combining clinical, scientific, and industrial expertise will add a new dimension to the treatment of cancer in women. The USD 7.8 million project from the European Commission will develop and test new methods for screening, diagnosing, and personalizing treatment of breast and ovarian cancer.

“We are proud of being a partner within the development of a DNA-based blood test that promotes new ways of diagnosing and treating patients with breast or ovarian cancer. The processing of samples in our ISO 17025 certified Genome & Diagnostic Center is one of our key competences”, commented Peter Pohl, CEO of GATC Biotech AG.

The collaborative project is led by Prof. Martin Widschwendter from the Department of Women’s Cancer at the University College London (United Kingdom). Collaborators include Charles University (Prague, Czech Republic), Ludwig Maximilians University (Munich, Germany), and companies with expertise in epigenetics and next generation screening (GATC Biotech, Germany), managing, and analyzing the large volumes of data created by these experiments (Genedata; Switzerland).

Implementation of successful screening programs has dramatically reduced the number of women dying from cervical cancer. Similarly, the EpiFemCare project aims to reduce the number of women who receive a diagnosis of breast or ovarian cancer when that cancer is already advanced by 50%, also reduce the number of women who receive unnecessary long-term chemotherapy by 50%, and reduce the number of women dying from these female cancers by 20%.

Related Links:

GATC Biotech
Department of Women’s Cancer at the University College London



Print article

Channels

Clinical Chemistry

view channel

New Approach Improves Identification of Women at High Risk of Preeclampsia

A new meta-analysis examining 92 cohort studies involving over 25 million pregnancies has provided an unprecedented understanding of risk factors for preeclampsia—some risk factors being strong enough to warrant that a pregnant woman starts on prophylactic treatment with acetylsalicylic acid (ASA) when she has only one.... Read more

Pathology

view channel

Liver Cancer May Be Diagnosed from Altered Sugar Metabolism

Altered gene expression that causes cancerous cells to metabolize fructose differently from healthy cells could be a significant new biomarker for diagnosing liver cancer. Dietary fructose is primarily metabolized in the liver and it has now been demonstrated that, compared with normal hepatocytes, hepatocellular carcinoma... Read more

Lab Tech.

view channel

Method Preserves Microfluidic Devices for HIV Monitoring in Developing Countries

Microfluidic devices with immunochemistry have broad applications in chemotherapy monitoring, transplant patient monitoring, and especially in monitoring the efficacy of antiretroviral therapy. Providing vital health care services to people in developing countries without reliable electricity, refrigeration and state-of-the-art... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.